Date of Award

2024

Document Type

Thesis

Degree Name

Master of Science (M.S.)

Department

Pharmaceutical and Chemical Sciences

First Advisor

Mamoun M. Alhamadsheh

First Committee Member

William K. Chan

Second Committee Member

Jianhua Ren

Abstract

Nanobodies, also known as single-domain antibodies, are the variable heavy chain fragments of heavy chain-only antibodies with a molecular weight of ~15 kDa. Antibodies and nanobodies can selectively bind to a specific antigen; however, nanobodies have approximately 1/10th the molecular weight of antibodies. Nanobodies have been commonly used for stabilizing proteins in x-ray crystallography studies. More recently, nanobodies have been used for therapeutic purposes. In 2019, the FDA approved the first nanobody-based therapeutic. The myriad benefits of nanobodies include their stability in varying environments, ease of manufacturing, and good tumor penetration due to their smaller size. However, due to their small size, nanobodies suffer from a short half-life.Previously, our laboratory designed and developed novel methods to increase the half-life of small molecules, peptides, and proteins. Utilizing the past successes in developing half-life extension strategies, the ultimate goal of this study was to design novel ways to increase the half-life of nanobody therapeutics. We plan to use an anti-HER2 nanobody as a proof of concept. In this work, we report on the optimization processes in expressing and purifying the anti-HER2 nanobody. While expressing nanobodies in the periplasm using a BL21(DE3) E. coli host proved to be difficult, the most optimized protein expression method in the cytoplasm utilized a Rosetta-gami B(DE3) pLysS E. coli host with induction at 0.25 mM IPTG, 225 rpm, and 18°C for 16 hours.

Pages

51

Available for download on Tuesday, December 11, 2029

Share

COinS
 

Rights Statement

Rights Statement

In Copyright. URI: http://rightsstatements.org/vocab/InC/1.0/
This Item is protected by copyright and/or related rights. You are free to use this Item in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s).